drugset
drugset / Trial / NCT04372706

RTX-240 Monotherapy and in Combination With Pembrolizumab

NCT04372706 ↗

Phase 1/2 Terminated 69 enrolled Rubius Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 monotherapy or in combination of pembrolizumab for the treatment of patients with (1) relapsed/refractory R/R or locally advanced solid tumors (Phase 1/2) or (2) R/R Acute Myeloid Leukemia (AML) (Phase 1 only).

Timeline

Start
2020-05-06
Primary completion
2022-11-30
Completion
2022-11-30

Outcome

Outcome not reported

Stopped: “Sponsor terminated study during expansion on 11/30/22. RTX-240 was well-tolerated in multiple indications, combinations, and dose levels (69pts). No DLTs, related deaths or SAEs were reported. RTX-240 cleared circulation rapidly.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody — —
Subject RTX-240 Cell therapy — —

Indications

acute myeloid leukemia